FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug
Category: Cancer
Opivibo, the first cancer immunotherapy drug in China, approved by the Chinese National Drug Administration and Supervision Agency for indications of treatment non-small cell lung cancer with history
🔬RIKEN: Elucidation of the relation between genome integration of hepatitis B virus and canceration
🔬Hitachi to begin demonstration test on cancer test using urine specimen
🏥Shimadzu Corporation signs a collaborative research agreement with the National Cancer Institute with measurement technology on cancer immunotherapy 2018/01/15